HEXAXIM

This brand name is authorized in Brazil, Ecuador, Hong Kong, New Zealand, Singapore, Tunisia, Turkey, South Africa

Active ingredients

The drug HEXAXIM contains a combination of these active pharmaceutical ingredients (APIs):

1 Diphtheria toxoid UNII IRH51QN26H - CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Diphtheria toxoid

2 Pertussis filamentous hemagglutinin UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

3 Haemophilus influenza type b polysaccharide conjugated to tetanus protein

Read about

4 Hepatitis B, purified antigen UNII IFJ010MNE4 - HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. Read about Hepatitis B, purified antigen

5 Pertussis toxoid

Read about Pertussis toxoid

6 Poliovirius (inactivated) type 1 (Mahoney) UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 1

7 Poliovirius (inactivated) type 2 (MEF-1) UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 2

8 Poliovirius (inactivated) type 3 (SAUKETT) UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 3

9 Tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07CA09	Diphtheria-Haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B	J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 576720050069717, 576720050069817, 576720050069917, 576720050070007
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 10-MBE-0614
Country: HK	Department of Health Drug Office	Identifier(s): 64983
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 16051
Country: SG	Health Sciences Authority	Identifier(s): 14834P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 12063091
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699625960527, 8699625960534, 8699625960565, 8699625960572
Country: ZA	Health Products Regulatory Authority	Identifier(s): 46/30.1/0447